Hum. Reprod. Advance Access originally published online on April 22, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Reproduction, Vol. 19, No. 6, 1418-1425,
June 2004
© 2004 European Society of Human Reproduction and Embryology
Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study
1 Fertility Center and 2 Department of Urology, Malmö University Hospital, Lund University, Malmö and 3 Department of Oncology, Lund University Hospital, Lund University, Lund, Sweden
4 To whom correspondence should be addressed: at Department of Oncology, Lund University Hospital, SE 221 85 Lund, Sweden. e-mail; jakob.eberhard{at}kir.mas.lu.se
BACKGROUND: Testicular cancer (TC) patients have a high survival rate, and the question of post-therapy recovery of sperm production and its dependence on genetic predisposition is of major interest. METHODS: Ejaculates were obtained from 112 TC patients at one or more of the following time points: post-orchidectomy, or 6, 12, 24, 36 and 60 months post-therapy. The lengths of the androgen receptor (AR) function modulating CAG and GGN repeats in leukocyte DNA were also analysed. RESULTS: No significant decrease in sperm concentration was seen in men who received 1–2 cycles of adjuvant chemotherapy (ACT). Radiotherapy (RT) or more than two cycles of chemotherapy (HCT) caused an initial decline in sperm concentration, which returned to pre-treatment levels 2–5 years after therapy. In the HCT group, sperm concentration 12–24 months post-treatment (T12–24) was inversely correlated with CAG length (
= –0.72, P = 0.03). The type of treatment, but not the concentration at T0, was an independent predictor of sperm concentration at T6 (P < 0.0005) and T12–24 (P = 0.004). CONCLUSION: ACT did not induce a significant decline in sperm concentration. After HCT and RT, a significant reduction of sperm concentration was observed, recovering to pre-treatment levels 2–5 years post-treatment. In HCT-treated patients, the AR CAG length influenced the recovery of spermatogenesis.
Key words: androgen receptor/chemotherapy/radiotherapy/semen quality/testicular cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Tandstad, O. Dahl, G. Cohn-Cedermark, E. Cavallin-Stahl, U. Stierner, A. Solberg, C. Langberg, R. M. Bremnes, A. Laurell, H. Wijkstrom, et al. Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program J. Clin. Oncol., May 1, 2009; 27(13): 2122 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Eberhard, O. Stahl, M. Cwikiel, E. Cavallin-Stahl, Y. Giwercman, E. C. Salmonson, and A. Giwercman Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur. J. Endocrinol., April 1, 2008; 158(4): 561 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Stahl, J. Eberhard, K. Jepson, M. Spano, M. Cwikiel, E. Cavallin-Stahl, and A. Giwercman Sperm DNA integrity in testicular cancer patients Hum. Reprod., December 1, 2006; 21(12): 3199 - 3205. [Abstract] [Full Text] [PDF]
|
|